 BUFFALO, N.Y., July 19, 2021 GLOBE NEWSWIRE -- Athenex, Inc., NASDAQ: ATNX, a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its partner, Almirall Almirall, S.A., BME: ALM, has received approval from the European Commission to market Klisyri tirbanibulin, indicated for the topical treatment of actinic keratosis AK of the face or scalp in adults. Almirall launched Klisyri in the U.S. in February 2021 and will be launching the product in Europe. 